# WAT earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/WAT) · [Earnings tab](https://www.lopjlb.com/stock/WAT?tab=earnings)

Updated: 2026-11-03T06:26:15

Quarters analyzed: 8

## Cross-quarter narrative

Over eight quarters Waters shifted from modest recovery to sustained double-digit organic growth. The 2024 Q3 inflection — instruments growing after a seven-quarter decline — began a string of guidance raises: FY24 organic guide narrowed to near-flat, FY25 lifted twice to 5.5–7.5% CC, then FY26 guided at ~5.3% blended before being raised to 7–9% organic in Q2 2026. The BD acquisition moved from pending (Q3 2025) to closed (Q4 2025) to integration ahead of plan (Q1 2026), adding revenue synergies and a 7% revenue CAGR target. Six product launches remain on schedule for 2026. Idiosyncratic drivers (GLP-1, PFAS, India generics, biologics) have persisted. However, headwinds crystallized in Q2 2026: China regulatory constraints (DRG, export licenses) and a stronger dollar offset margin gains from cost actions; instrument replacement cycles appear to be elongating below the historic 5% CAGR; pricing initiatives targeting 150bps net contribution face timing uncertainty; and competitive pressure in flow cytometry emerged. Biotech/discovery demand has remained pressured since early 2025. The narrative evolved from cyclical recovery to structural growth with integration upside, tempered by geographic and macro cross-currents. Management tone stayed consistently positive (0.7–0.8) with QA pressure appearing only in the latest quarter (0.6).

## Latest CallCard · Q2

Waters beat Q2 2026 expectations, raised full-year organic revenue guidance to 7-9%, highlighted strong BD acquisition growth, new product launches and cost actions while noting China headwinds.

**Guidance:** raised — raised full-year organic constant‑currency revenue growth to 7‑9% and increased BD revenue guidance

**Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.2

executed ahead of guidance, strong growth across divisions and new product launches

### Demand visibility

Strong visibility on pharma reshoring sites and upcoming product launches

Tracking 76 expansion sites (~$100B capex), ~70% of which are Waters accounts; localized flow cytometry portfolio in China Q4; FACSDiscover A7 launch Sep 15 provides additional visibility

### Margins / costs

Cost actions improve margin but stronger dollar offsets gains

Cost actions deliver $25M operating income benefit Q3 and $50M Q4 (~75M total); 30bps margin improvement offset by stronger USD, adjusted gross margin 54%

### Capital allocation

Focus on cost actions, pricing initiatives and strategic product investments

Free cash flow $202M; $200M run‑rate cost‑action program; pricing desk achieving 90bps net price realization; deal‑desk model for discounting; investment in new instruments (A7, FXI)

### Milestones

- **Cyclic IMS P20 launch** [on_track]: High‑resolution mass spec product released, improves sensitivity for omics
- **Xevo MRT P10 launch** [on_track]: Bench‑top high‑throughput mass spec set new speed standard
- **BioResolve Peptide column launch** [on_track]: Industry‑first particle optimization for GLP‑1 peptides
- **GTxResolve Lipid column launch** [on_track]: Industry‑first lipid column with double resolving power
- **Xevo TQ Absolute XR IVD launch** [on_track]: Most sensitive clinical IVD mass spec, 5x sensitivity increase
- **Coin Cell DSC launch** [on_track]: New battery thermal analysis instrument capturing thermal, gas and electrochemical data
- **FACSDiscover A7 launch** [on_track]: Spectral flow cytometer debut Sep 15, fills portfolio gap
- **BACTEC FXI FDA 510(k) clearance** [on_track]: Next‑gen blood culture system launched in US, Japan, Europe

### Fears / risks

- **China regulatory headwinds**: DRG constraints and export‑license delays could limit growth in Flow Research and Diagnostics
- **Foreign exchange impact**: Stronger USD erodes margin and offsets cost‑action benefits
- **Pricing ramp uncertainty**: Achieving 150bps net price contribution may take longer than anticipated
- **Instrument replacement cycle lengthening**: Organic instrument revenue growth below historic 5% CAGR, indicating elongated cycles
- **Competitive pressure in flow cytometry**: Rival products could challenge adoption of A7 and localized portfolio
- **Tariff refund neutrality**: Potential need to reverse surcharge credits could affect EPS
- **Integration costs from BD acquisition**: Amortization of intangibles and inventory step‑up added GAAP loss per share
- **Reshoring timing risk**: Benefit from pharma reshoring may materialize later than 2027‑2030 horizon

### Key quotes

> “We delivered an excellent second quarter, executing ahead of guidance across all 4 divisions as a powerful new era of growth extends across Waters.” — Udit Batra

## Quarter one-liners

- **2026 Q2:** Waters beat Q2 2026 expectations, raised full-year organic revenue guidance to 7-9%, highlighted strong BD acquisition growth, new product launches and cost actions while noting China headwinds.
- **2026 Q1:** Waters Q1 2026: 11% organic CC growth, raised FY guidance, BD integration ahead of plan with 180-day plan driving operational improvements and early revenue synergies.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted excellent first quarter, double-digit organic growth, raised full-y
- **2025 Q4:** Waters Q4: 6% CC revenue growth, 11% adj EPS growth; BD acquisition closed; 2026 guide ~5.3% blended CC growth with $55M cost/$50M revenue synergies; 5 idiosyncratic drivers including biologics/informatics.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted strong Q4 results, transform
- **2025 Q3:** Waters Q3 2025 beats guidance with 8% sales growth, raises full-year outlook to 7% midpoint, driven by instrument replacement cycle, GLP-1/PFAS/India generics, bioseparations innovation, and pending BD combination on track for Q1 2026 close.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management empha
- **2025 Q2:** Waters Q2 sales beat guidance with 8% CC growth, raised FY25 outlook to 5.5-7.5% CC sales growth and $12.95-13.05 EPS; BD combination on track with 7% revenue CAGR and mid-teens EPS CAGR targets.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted strong quarter above guidance, raised f
- **2025 Q1:** Waters Q1 2025: 7% cc sales growth, 11% instrument growth led by Pharma; raised FY25 guidance to 5-7% cc sales and $12.75-$13.05 EPS; tariff impact largely mitigated via supply chain actions and pricing; GLP-1, PFAS, India driving idiosyncratic growth. Biotech/discovery remains pressured. A&G fundin
- **2024 Q4:** —
- **2024 Q3:** Waters Q3 beats with 4% sales growth, instruments grow after 7-quarter decline, raises FY24 guide to -0.9% to -0.3% organic CC on Pharma LC, PFAS, GLP-1 strength.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights strong Q3 beat, instrument growth inflection, recurring revenue accelerat

## Theme arcs

- **Revenue growth trajectory** (improving): From -0.9% to -0.3% organic in FY24 to 11% organic in Q1 2026; guidance raised repeatedly.
- **Instrument replacement cycle** (improving): Inflected positive in Q3 2024 after 7-quarter decline; drove growth through 2025, though Q2 2026 notes elongation below historic 5% CAGR.
- **BD acquisition integration** (improving): Progressed from pending to closed to ahead-of-plan integration with early revenue synergies and 7% revenue CAGR target.
- **China geographic exposure** (deteriorating)

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/WAT`